Print Issue: May 01, 2007

When to Use Intravesical Therapies

Bladder cancer is projected to be the fourth most common cancer diagnosed in 2007 and the eighth most common cause of cancer-specific death in men, according to the American Cancer Society. Approximately 70% of bladder tumors present as non-muscle invasive (NMI) disease and 10%-20% will progress to muscle invasion.

For Refractory Strictures, A Better Option

SEATTLE—Cutting balloon ureteroplasty may be a safe and effective treatment option for anastomotic strictures resistant to conventional high-pressure balloon dilation, according to findings presented here at the Society of Interventional Radiology’s 31st Annual Scientific Meeting.

Review for Preventive Kidney Injury Therapy

SR Pharma PLC, of London, announced that the FDA has accepted its Investigational New Drug application (IND) for AKIi-5, a small interfering RNA (siRNA) therapeutic for the prevention of acute kidney injury (AKI) in high-risk patients undergoing major cardiovascular surgery.

Immunotherapy for Prostate Cancer Endorsed

FDA’s Office of Cellular, Tissue and Gene Therapies Advisory Committee recommended to the agency that there is substantial evidence of efficacy and safety of Provenge (sipuleucel-T), made by Dendreon Corporation of Seattle, for treating patients with hormone refractory prostate cancer.

Next post in News